Pharmaceutical Executive
Despite generics' increasing market share and the slowed pace of blockbuster discoveries, the industry has reason for optimism. A recent IMS World Review report shows that audited global pharmaceutical sales grew 12 percent in 2001.
Despite generics' increasing market share and the slowed pace of blockbuster discoveries, the industry has reason for optimism. A recent IMS World Review report shows that audited global pharmaceutical sales grew 12 percent in 2001. The report tracks sales of approximately 90 percent of all prescription medications and certain over-the-counter products in 70 countries.
2001 Global Pharmaceutical Sales by Region
IMS estimates 2001 global pharma sales were $392 billion, with North America, Europe, and Japan accounting for 87 percent of that. North America was again the most dynamic region, garnering $181.1 billion-almost half
of total sales. Europe's growth was up 10 percent to $88 billion. Japan's grew slowly but steadily at 4 percent, reaching $47.6 billion. Latin Ameri-can sales were flat, while sales in Asia (excluding Japan), Africa, and Australia, increased 9 percent.
Leading Therapy Classes in 2001 Global Pharmaceutical Sales
The report showed that anti-ulcerants' 14 percent growth helped it remain the leading therapeutic class worldwide, as it has for the past 11 years, representing 6 percent of all sales. AstraZeneca's Prilosec (omeprazole)-with $6.1 billion in sales-represents 32 percent of the class. Cholesterol reducers, ranked second, grew 22 percent to $18.9 billion. A major factor in that growth is the world's top-selling medicine, Pfizer's Lipitor (atorvastatin), which was up 31 percent to $7 billion.
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
October 23rd 2024Peter Marks, director, Center for Biologics Evaluation and Research, FDA, presented the keynote presentation on the future of gene therapy as part of the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.